乳腺癌 z-bo 2020-12-16 373

　　Recently, researchers at Boston University School of Medicine (BUSM) have identified a gene that plays a role in the development of breast cancer to metastatic disease. It can help predict the progression of the disease and serve as a target for future breast cancer therapies.

　　 Researchers have identified a gene called serum deprivation response (SDPR) and the mechanism by which this gene is down-regulated or silenced in breast cancer cells that promote tumor spread. Using the breast cancer progression model, the research team found that invasive and metastatic breast cancer cells have little or no SDPR gene expression. In addition, when this gene is overexpressed (or turned on) in a breast cancer cell model with metastatic tendency, The incidence of metastatic disease is significantly reduced. Although advanced technologies have emerged, new tumor metastasis suppressor genes (such as SDPR) have been discovered through genomic research to prevent breast cancer from spreading to remote sites. Work in this area has been relatively slow because they are mainly based on appearance. The regulation mode of genetic mechanism, BUSM researchers elaborated in this study. The current research has revealed the importance of gene regulation through epigenetic mechanisms (rather than genetic mechanisms), so that cancer cells can easily adapt to the new microenvironment of various human organs far away from the initial site where cancer cells form. According to the researchers, this work is critical, because the metastatic spread of breast cancer cells is a significant clinical obstacle for curative treatment. The spread of cancer is the main cause of death in breast cancer and other cancer patients. the reason. Sam Thiagalingam, associate professor of medicine, genetics and genomics, pathology and experimental medicine at Boston University School of Medicine, explained: “This is extremely important for understanding the underlying molecular mechanisms that promote/prevent cancer metastasis.” The researchers also found that SDPR deletion is not limited to breast cancer, because a computer simulation meta-analysis based on publicly available data found that tumor samples from bladder cancer, colon cancer, lung cancer, pancreatic and ovarian cancer, and sarcoma also showed SDPR The loss of expression indicates that its function as a metastasis suppressor gene may affect a variety of cancers. Thiagalingam added: “Although this is a major advancement in deciphering the molecular basis of metastatic disease, and may help predict the progression of metastatic cancer, its potential importance in the development of future precision cancer therapies needs to be approved by SDPR. The identification of regulated drug targets has been confirmed."